Michael Payer

Prof. Michael Payer


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2020 in Clinical Oral Implants Research
Verified
Journal Article
Open access
PDF file
MKMartin Koller
Martin Koller
ESElisabeth Steyer
Elisabeth Steyer
KTKerstin Theisen
Kerstin Theisen
SSSami Stagnell
Sami Stagnell
NJNorbert Jakse
Norbert Jakse
MPMichael Payer
Michael Payer
Objectives: To prospectively evaluate, as part of an ongoing randomized pilot trial, the clinical outcomes of two‐piece zirconia implants in comparison with titanium implants 80 months after delivery of all‐ceramic (lithium disilicate) single‐tooth restorations.Material and methods: The original sample included 31 (16 zirconia and 15 titanium) implants in 22 healthy patients. In addition to evaluating implant survival and success, a number of clinical or radiographic parameters were statistically analyzed: plaque index (PI), bleeding on probing (BOP), pink esthetic score (PES), and marginal bone loss (MBL). Both implant groups were compared using a Mann–Whitney U test.Results: Three implants (2 zirconia and 1 titanium) had been lost, so that 28 implants (14 zirconia and 14 titanium) in 21 patients could be evaluated after a mean of 80.9 (SD: 5.5) months. All surviving implants had remained stable, in the absence of any fixture or abutment fractures and without any chipping, fracture, or debonding of crowns. The zirconia implants were associated with PI values of 11.07% (SD: 8.11) and the titanium implants with 15.20% (SD: 15.58), the respective figures for the other parameters being 16.43% (SD: 6.16) or 12.60% (SD: 7.66) for BOP; 11.11 (SD: 1.27) or 11.56 (SD: 1.01) for PES; and 1.38 mm (SD: 0.81) or 1.17 mm (SD: 0.73) for MBL.Conclusions: No significant differences were found between the clinical outcomes of two‐piece zirconia and titanium implants based on the aforementioned parameters after 80 months of clinical service. Our results should be interpreted with the limited sample size in mind.

15 February 2012 in Clinical Oral Implants Research
Verified
Journal Article
Closed access
PDF file
MPMichael Payer
Michael Payer
VAVincent Arnetzl
Vincent Arnetzl
RKRobert Kirmeier
Robert Kirmeier
MKMartin Koller
Martin Koller
GAGerwin Arnetzl
Gerwin Arnetzl
NJNorbert Jakse
Norbert Jakse

23 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Valentin HerberValentin Herber
Valentin Herber
BOBegüm Okutan
Begüm Okutan
Antonoglou Georgios N.Antonoglou Georgios N.
Antonoglou Georgios N.
Nicole Gabriele SommerNicole Gabriele Sommer
Nicole Gabriele Sommer
MPMichael Payer
Michael Payer
Bone preservation and primary regeneration is a daily challenge in the field of dental medicine. In recent years, bioresorbable metals based on magnesium (Mg) have been widely investigated due to their bone-like modulus of elasticity, their high biocompatibility, antimicrobial, and osteoconductive properties. Synthetic Mg-based biomaterials are promising candidates for bone regeneration in comparison with other currently available pure synthetic materials. Different alloys based on Mg were developed to fit clinical requirements. In parallel, advances in additive manufacturing offer the possibility to fabricate experimentally bioresorbable metallic porous scaffolds. This review describes the promising clinical results of resorbable Mg-based biomaterials for bone repair in osteosynthetic application and discusses the perspectives of use in oral bone regeneration.

29 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KZKatharina Zwittnig
Katharina Zwittnig
BKBarbara Kirnbauer
Barbara Kirnbauer
NJNorbert Jakse
Norbert Jakse
Peter SchlenkePeter Schlenke
Peter Schlenke
IMIrene Mischak
Irene Mischak
TZTomislav Zrnc
Tomislav Zrnc
Aim: The purpose of this study was to obtain data concerning growth factor release within liquid and solid platelet-rich fibrin (PRF) matrices and to estimate the amount of potential interindividual variations as a basis for further preclinical and clinical trials. Therefore, we aimed to determine possible differences in the release of growth factors between liquid and solid PRF. Materials and Methods: Blood samples obtained from four subjects were processed to both liquid and solid PRF matrices using a standard centrifugation protocol. Five growth factors (vascular endothelial growth factor, VEGF; epidermal growth factor, EGF; platelet-derived growth factor-BB, PDGF-BB; transforming growth factor-β1, TGF-β1; and matrix metallopeptidase 9, MMP-9) have been evaluated at six time points by ELISA over a total observation period of 10 days (1 h, 7 h, 1 d, 2 d, 7 d, and 10 d). Results: Growth factor release could be measured in all samples at each time point. Comparing liquid and solid PRF matrices, no significant differences were detected (p > 0.05). The mean release of VEGF, TGFβ-1, PDGF-BB, and MMP-9 raised to a peak at time point five (day 7) in both liquid and solid PRF matrices. VEGF release was lower in liquid PRF than in solid PRF, whereas those of PDGF-BB and MMP-9 were higher in liquid PRF than in solid PRF at all time points. EGF had its peak release already at time point two after 7 h in liquid and solid matrices (hour 7 EGF solid: mean = 180 pg/mL, SD = 81; EGF liquid: mean = 218 pg/mL, SD = 64), declined rapidly until day 2, and had a second slight peak on day 7 in both groups (day 7 EGF solid: mean = 182 pg/mL, SD = 189; EGF liquid: mean = 81 pg/mL, SD = 70). Conclusions: This study detected growth factor release within liquid and solid PRF matrices with little variations. Further preclinical trials are needed to precisely analyze the growth factor release in larger samples and to better understand their effects on wound healing in different clinical indications.

THTamás Hegedüs
Tamás Hegedüs
PKPatrik Kreuter
Patrik Kreuter
AKAron Attila Kismarczi-Antalffy
Aron Attila Kismarczi-Antalffy
TDTamas Demeter
Tamas Demeter
DBDorottya Banyai
Dorottya Banyai
Daniel VeghDaniel Vegh
Daniel Vegh
Background: 3D printing is a rapidly developing technology in the healthcare industry and in dentistry. Its application clearly shows that this area of digital dentistry has potential for everyday usage across all fields, including prosthodontics, orthodontics, maxillofacial surgery, and oral implantology. However, despite gaining ground, there is a lack of information about how specialists (dentists and dental technicians) use additive technology. Our research group aimed to investigate the impact of social media on additive manufacturing technology among dental specialists and their everyday usage of 3D printing. Methods: This paper investigated specialists’ everyday usage of 3D printers via an online survey (Google Forms). The survey questions aimed to discover the number of 3D printers used, the accessibility of the devices, the annual cost, and the design programs. Since specialists tend to build online communities on social media, we circulated our study questionnaire using our profiles on LinkedIn, Facebook, and Instagram platforms during our research. Results: A total of 120 responses were received from 20 countries, with the most significant numbers being from Hungary 23.7% (n = 27), the United States 18.4% (n = 21), and the United Kingdom 7.9% (n = 9). Most of the participants were dentists (n = 68) or dental technicians (n = 29), but some CAD/CAM specialists (n = 23) also completed our survey. The participants had an average of 3.8 years (±0.7) of experience in the 3D printing field, and owned a total of 405 printing devices (3.6 on average/person). Conclusions: The impact of social media on this research field is growing increasingly. Hence, we support specialists in joining virtual communities on professional platforms. This article intended to provide a practical overview, feedback, and direction for dentists interested in 3D printing technology. From our survey, we can conclude that additive technology is broadening dental applications and the services that we can provide for our patients.

19 January 2020 in Clinical Oral Implants Research
Verified
Journal Article
Open access
PDF file
MPMichael Payer
Michael Payer
WTWah Ching Tan
Wah Ching Tan
JHJie Han
Jie Han
SISaso Ivanovski
Saso Ivanovski
NMNikos Mattheos
Nikos Mattheos
TGthe International Team for Implantology (ITI) Antibiotic Study Group
the International Team for Implantology (ITI) Antibiotic Study Group
Objectives: The aim of the present superiority study was to determine the effect of systemic antibiotics primarily on patient‐reported outcome measures (PROMs) and post‐surgical complications in patients undergoing oral implant therapy with simultaneous guided bone regeneration (GBR).Materials and Methods: A total of 236 medically and periodontally healthy patients received oral implants with simultaneous GBR at seven centres. Pre‐operative antibiotics of 2 g amoxicillin were prescribed to the test group 1 hr prior to surgery and 500 mg thrice daily on days 1–3 after surgery. The control group was given a placebo. Group allocation was performed randomly. Primary outcome variables were PROMs recorded as visual analogue scale scores assessed on days 1–7 and 14 on pain, swelling, haematoma and bleeding. Post‐operative complications as secondary outcome variables were examined at 1, 2, 4 and 12 weeks from surgery. Chi‐square tests and repeated measures of analysis of variance (ANOVA) were performed for statistical evaluation.Results: No statistically significant differences (p > .05) between the two groups were detected for the evaluated PROMs. The same was noted with respect to post‐surgical complications. Four implants were lost—three in the test group and one in the control group.Conclusion: In this trial, systemic antibiotics did not provide additional benefits to PROMs, nor the prevention of post‐surgical complications in medically and periodontally healthy patients undergoing oral implant therapy with simultaneous GBR. However, further studies with larger sample sizes are still required to support the clinical outcomes of this study.